x
05/2022 Portfolio

HEMOTUNE WINS GERMAN INNOVATION AWARD

Congratulations to the whole team for winning the German Innovation Award 2022 in the medical technologies category.

Our Swiss portfolio company, active in the field of blood purification, was able to convince the renowned jury, which particularly appreciated hemotune’s achievements in the areas degree of innovation, user benefit and efficiency. In addition, the German Innovation Award honors products and solutions that distinguish themselves through social, ecological and economic sustainability as well as energy and resource consumption. All these values are also important to us at OCCIDENT as a basis for sustainable success in the future, which has repeatedly convinced us to invest.

More information in the press release under the following link.

More about hemotune

05/2022 PORTFOLIO

LUNAPHORE WINS AWARD

Congratulations to our portfolio company Lunaphore. The Lausanne-based diagnostics company won the MedTech Breakthrough Award for the Best New Technology Solution in Drug Development.

The award was granted by MedTech Breakthrough, an independent market research organization that recognizes the world’s most groundbreaking companies, people, platforms and products in the healthcare and medical technology sectors.

The award recognizes Lunaphore’s technological achievements, including its flagship product COMET™, which enables research applications and the development of targeted therapies in immuno-oncology and immunology.

More information in the press release under the following link.

More about Lunaphore

05/2022 PORTFOLIO

FOLLOW-UP INVESTMENT IN TUBULIS

OCCIDENT participated in this € 60 million Series B led by Andera Partners with participation from new investors Evotec and Fund+. Also, it is very pleasing to see all existing investors participating in this financing, including Bayern Kapital, Bio­Med­Partners, coparion, High-Tech Gründerfonds and Seventure Partners.

The additional capital will enable the Munich based biotech company to access the true therapeutic potential of antibody drug conjugates (ADCs) by further progressing its proprietary pipeline of uniquely matched ADCs as well as advancing its novel programs addressing a range of solid tumor indications towards clinical evaluation.

More information in the press release under the following link.

More about Tubulis

04/2022 PORTFOLIO

FOLLOW-UP INVESTMENT IN HEMOTUNE

OCCIDENT has again taken the lead in the latest financing round of hemotune. With the fantastic support of existing and new investors, we are very pleased to contribute to such a relevant therapeutic area as sepsis with a technology that can benefit many patients in the future.

The team at hemotune has done a tremendous job over the last years and convinced us once again. With this funding, the company will be able to continue the very encouraging development of its platform device.

More information in the press release under the following link.

More about hemotune

04/2022 PORTFOLIO

RESISTELL STARTS RESEARCH PROJECT WITH PFIZER

Congratulations to our portfolio company Resistell for entering into a research project with the US-pharmaceutical company Pfizer. Goal of this project is to provide a pre-clinical proof of concept of Resistell’s Antibiotic Susceptibility Test for a novel antibiotic.

Multi-drug resistant bacterial infections represent a key challenge for today’s global healthcare systems. Resistell is developing the world’s fastest Antibiotic Susceptibility Test which provides highly accurate results in just four hours, thereby setting a new industry benchmark.

A positive outcome of the research project may contribute to a paradigm shift in the treatment of bacterial infections. This could help healthcare professional to improve therapy decisions and drastically enhance patient treatment.

More information in the press release under the following link.

More about Resistell

03/2022 TEAM

WELCOME OLIVIA

OCCIDENT welcomes Olivia Adler as new Team Assistant & Office Manager at the Zug office. In addition to her studies in Global Business Management, Olivia gained professional experience in event and account management, and is also founder of a startup.

01/2022 About

OCCIDENT HAS BEEN CLIMATE NEUTRAL FOR MANY YEARS

Even a small contribution can change our future if everyone takes responsibility for their carbon foot­print!

In keeping with our philosophy of making a positive contribution to society through sustainable investments, we have been supporting climate neutrality initiatives for many years. Specifically, we have also calculated our corporate carbon footprint for the year 2021 and, based on this, support various CO2 reduction projects in collaboration with the Swiss foundation myclimate.

More about myclimate

12/2021 About

LET'S MAKE THE UNTHINKABLE THINKABLE!

The last two years have shown us all more than ever how revolutionary technologies can help us humans to be better off, healthier, live safer and work more efficiently.

We support startups in turning such technologies into forward-looking products. This is the goal that unites us.

Our motivation goes beyond technological fascination: it is the enthusiasm for the unprecedented, the curiosity for the impossible, the passion for profitable collaboration and the commitment to our goals.

We wish you a peaceful, inspiring Christmas season and a year full of new opportunities for 2022 – a year in which we can make the unthinkable thinkable together!

12/2021 Portfolio

ADIVO RECEIVES EIC ACCELERATOR GRANT

Congratulations to our biotech portfolio company adivo on its successful funding through the EIC Accelerator Program. This makes adivo one of only 99 highly innovative companies across Europe that the European Commission is supporting with a total of 627 million Euros to bring promising technologies to market.

adivo develops therapeutic antibodies for the treatment of serious and chronic diseases in companion animals. The EIC Accelerator Program will support the company to further develop their CAESAR-IBD project (treatment of canine inflammatory bowel disease) over the next two years and conduct initial clinical trials.

More information under the following link.

More about adivo.

Show more